A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-04449913 (GLASDEGIB), AN ORAL HEDGEHOG INHIBITOR, ADMINISTERED AS A SINGLE AGENT IN JAPANESE PATIENTS WITH SELECT HEMATOLOGIC MALIGNANCIES AND IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW-DOSE ARA-C, OR AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
Latest Information Update: 15 Jan 2024
At a glance
- Drugs Glasdegib (Primary) ; Azacitidine; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 10 Jan 2024 Status changed from active, no longer recruiting to completed.
- 12 Jan 2022 Planned End Date changed from 30 Nov 2021 to 31 Jan 2024.
- 30 Apr 2021 Planned End Date changed from 13 May 2021 to 30 Nov 2021.